<?xml version='1.0' encoding='utf-8'?>
<document id="26375942"><sentence text="Pharmacokinetic drug-drug interaction study between raltegravir and citalopram."><entity charOffset="52-63" id="DDI-PubMed.26375942.s1.e0" text="raltegravir" /><entity charOffset="68-78" id="DDI-PubMed.26375942.s1.e1" text="citalopram" /><pair ddi="false" e1="DDI-PubMed.26375942.s1.e0" e2="DDI-PubMed.26375942.s1.e0" /><pair ddi="false" e1="DDI-PubMed.26375942.s1.e0" e2="DDI-PubMed.26375942.s1.e1" /></sentence><sentence text="Depression is the most common mental health disorder among HIV-infected patients" /><sentence text=" When treating HIV-infected patients with a selective serotonin reuptake inhibitor (SSRI), potential drug-drug interactions with antiretroviral agents have to be taken into account"><entity charOffset="54-63" id="DDI-PubMed.26375942.s3.e0" text="serotonin" /></sentence><sentence text=" We investigated the two-way pharmacokinetic drug-drug interaction and tolerability of concomitant administration of the SSRI citalopram and the HIV-1 integrase inhibitor raltegravir in healthy volunteers" /><sentence text="" /><sentence text="An open-label, crossover, two-period trial was conducted in 24 healthy volunteers" /><sentence text=" Subjects received the following treatments: citalopram 20 mg once daily for 2 weeks followed by the combination with raltegravir 400 mg twice daily for 5 days and after a washout period raltegravir 400 mg twice daily for 5 days"><entity charOffset="45-55" id="DDI-PubMed.26375942.s7.e0" text="citalopram" /></sentence><sentence text=" Intensive steady-state pharmacokinetic blood sampling was performed" /><sentence text=" Geometric mean ratios (GMRs) of the combination versus the reference treatment and 90% CIs were calculated for the area under the plasma concentration-time curve (AUC)" /><sentence text=" CYP2C19 genotyping was performed because it influences N-demethylation of citalopram to desmethylcitalopram"><entity charOffset="75-85" id="DDI-PubMed.26375942.s10.e0" text="citalopram" /><entity charOffset="89-108" id="DDI-PubMed.26375942.s10.e1" text="desmethylcitalopram" /><pair ddi="false" e1="DDI-PubMed.26375942.s10.e0" e2="DDI-PubMed.26375942.s10.e0" /><pair ddi="false" e1="DDI-PubMed.26375942.s10.e0" e2="DDI-PubMed.26375942.s10.e1" /></sentence><sentence text="" /><sentence text="A total of 22 healthy volunteers completed the trial" /><sentence text=" GMRs (90% CI) were 1" /><sentence text="00 (0" /><sentence text="98, 1" /><sentence text="03) for citalopram AUC0-24 h, 0" /><sentence text="99 (0" /><sentence text="88, 1" /><sentence text="12) for desmethylcitalopram AUC0-24 h and 0" /><sentence text="77 (0" /><sentence text="50, 1" /><sentence text="19) for raltegravir AUC0-12 h" /><sentence text=" Raltegravir plasma concentration 12 h after intake (C12 h) did not change with concomitant use of citalopram"><entity charOffset="1-12" id="DDI-PubMed.26375942.s23.e0" text="Raltegravir" /><entity charOffset="99-109" id="DDI-PubMed.26375942.s23.e1" text="citalopram" /><pair ddi="false" e1="DDI-PubMed.26375942.s23.e0" e2="DDI-PubMed.26375942.s23.e0" /><pair ddi="false" e1="DDI-PubMed.26375942.s23.e0" e2="DDI-PubMed.26375942.s23.e1" /></sentence><sentence text=" Within each CYP2C19 phenotype subgroup the citalopram metabolite-to-parent ratio, which is a measure for metabolic enzyme activity, was not influenced by concomitant raltegravir use"><entity charOffset="44-54" id="DDI-PubMed.26375942.s24.e0" text="citalopram" /><entity charOffset="167-178" id="DDI-PubMed.26375942.s24.e1" text="raltegravir" /><pair ddi="false" e1="DDI-PubMed.26375942.s24.e0" e2="DDI-PubMed.26375942.s24.e0" /><pair ddi="false" e1="DDI-PubMed.26375942.s24.e0" e2="DDI-PubMed.26375942.s24.e1" /></sentence><sentence text="" /><sentence text="Raltegravir does not influence the pharmacokinetics of citalopram and desmethylcitalopram"><entity charOffset="0-11" id="DDI-PubMed.26375942.s26.e0" text="Raltegravir" /><entity charOffset="55-65" id="DDI-PubMed.26375942.s26.e1" text="citalopram" /><entity charOffset="70-89" id="DDI-PubMed.26375942.s26.e2" text="desmethylcitalopram" /><pair ddi="false" e1="DDI-PubMed.26375942.s26.e0" e2="DDI-PubMed.26375942.s26.e0" /><pair ddi="false" e1="DDI-PubMed.26375942.s26.e0" e2="DDI-PubMed.26375942.s26.e1" /><pair ddi="false" e1="DDI-PubMed.26375942.s26.e0" e2="DDI-PubMed.26375942.s26.e2" /><pair ddi="false" e1="DDI-PubMed.26375942.s26.e1" e2="DDI-PubMed.26375942.s26.e1" /><pair ddi="false" e1="DDI-PubMed.26375942.s26.e1" e2="DDI-PubMed.26375942.s26.e2" /></sentence><sentence text=" Citalopram did not change the pharmacokinetics of raltegravir in a clinically meaningful way"><entity charOffset="1-11" id="DDI-PubMed.26375942.s27.e0" text="Citalopram" /><entity charOffset="51-62" id="DDI-PubMed.26375942.s27.e1" text="raltegravir" /><pair ddi="false" e1="DDI-PubMed.26375942.s27.e0" e2="DDI-PubMed.26375942.s27.e0" /><pair ddi="false" e1="DDI-PubMed.26375942.s27.e0" e2="DDI-PubMed.26375942.s27.e1" /></sentence><sentence text=" The combination was well tolerated and can be administered without dose adjustments" /><sentence text=" ClinicalTrials" /><sentence text="gov NCT01978782" /><sentence text="" /></document>